The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...

Now, Christopoulos and colleagues have highlighted a novel mechanism of GPCR activation and signalling by showing that a muscarinic acetylcholine ... subtype- and pathway-selective GPCR agonists ...

(“Neurocrine”) regarding the clinical development of its partnered muscarinic agonist portfolio. These updates were presented by Neurocrine at the 43 rd Annual J.P. Morgan Healthcare Conferen ...

Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”) regarding the clinical development of its partnered muscarinic ...

Ltd. ("Nxera” or "the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. ("Neurocrine”) regarding the clinical development of its partnered muscarinic ...